Mineralys Therapeutics, Inc. (MLYS) stock
MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$15.33−0.17 (-1.10%)
Close on Nov 13, 2026Market cap $1.36BP/E –Yield –
Mineralys Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Mineralys Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$389.72M. For fiscal 2025 it was -$170.55M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$170.55M | – |
| FY2024 | Dec 31, 2024 | -$192.36M | – |
| FY2023 | Dec 31, 2023 | -$84.66M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$60.08M | – |
| Q2 FY2026 | Jun 30, 2026 | -$246.04M | – |
| Q1 FY2026 | Mar 31, 2026 | -$45.33M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.27M | – |
| Q3 FY2025 | Sep 30, 2025 | -$41.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$46.73M | – |
| Q1 FY2025 | Mar 31, 2025 | -$44.43M | – |
| Q4 FY2024 | Dec 31, 2024 | -$51.75M | – |
| Q3 FY2024 | Sep 30, 2024 | -$60.10M | – |
| Q2 FY2024 | Jun 30, 2024 | -$45.16M | – |
| Q1 FY2024 | Mar 31, 2024 | -$35.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.71M | – |
| Q3 FY2023 | Sep 30, 2023 | -$26.27M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.74M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.94M | – |
See a number that looks wrong?